TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32068688
Drug: NT-814 100
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NT-814 100 mg
Study: 33734828
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg atomoxetine + 5 mg solifenacin succinate (ato-sol)
Study: 34538402
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with durvalumab 4-weekly for one year plus two doses of tremelimumab (CTLA-4 inhibitor) at day 1 of the first two 4-weekly cycles (Arm C)
Study: 35651299
Drug: Clemastine fumarate
Normalized name: Clemastine Fumarate
DrugBank: Clemastine (DB00283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clemastine fumarate injection
Study: 35344474
Drug: Online hypnotic
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Online hypnotic intervention for 7 weeks
Study: 37103592
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT)
Study: 32801167
Drug: Cladribine tablets
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine tablets (10 mg, cumulative dose 3.5 mg/kg over 2 years)
Study: 33999753
Drug: Standard Tru-Cut
Normalized name: Tru-micin
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Tru-Cut needle (BARD 18 G)
Study: 34705137
Drug: Early Botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early Botulinum toxin injection
Study: 38625671
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg
Study: 36284645
Drug: Favipiravir 1800
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Favipiravir 1800 mg on day 1, then 800 mg twice daily for 14 days
Study: 37730405
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (control group)
Study: 38015467
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg
Study: 33567780
Drug: Spirulina maxima
Normalized name: SPIRULINA MAXIMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina maxima intake (5 g/day) + Exercise program
Study: 34726026
Drug: Classic rehabilitation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classic rehabilitation training, performed twice a week for 12 weeks.
Study: 35274222
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg warfarin
Study: 33513645
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy
Study: 33878154
Drug: Golimumab (GLM)
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab (GLM) 50 mg every 4 weeks during the OLE
Study: 34933416
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy (testosterone undecanoate injection three times/6 months, n=20)
Study: 35241720
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg QD
Study: 33407599
Drug: Whole tomato
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole tomato food supplement (WTFS) 5g daily for 2 months
Study: 33242163
Drug: Systemic treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatment (ST)
Study: 35488544
Drug: HEV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEV vaccine administered at 0, 1, and 6 months
Study: 33212540
Drug: Low-Dose Computed
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-Dose Computed Tomography (LDCT) screening
Study: 32448257
Drug: 600mcg oral
Normalized name: Fentanyl Citrate 600mcg Oral lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mcg oral misoprostol given to all women after delivery (primary prevention)
Study: 36326117
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of RAS inhibitors
Study: 32543080
Drug: Trigone-involved Botox
Normalized name: Botox
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigone-involved Botox injection (100 IU intradetrusal)
Study: 32484940
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 100 μg/d
Study: 35334862
Drug: Low-dose whey
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose whey protein concentrate (WPC)
Study: 32178765
Drug: Guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 100 mg every 4 weeks
Study: 39083288
Drug: Guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 100 mg every 8 weeks
Study: 32856211
Drug: Immune-suppressive therapy
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune-suppressive therapy
Study: 36458679
Drug: Desidustat 50
Normalized name: Desidustat
DrugBank: Desidustat (DB16135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desidustat 50 mg orally
Study: 38133925
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin
Study: 35148706
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) counseling in 8 sessions of 60 to 90 minutes
Study: 34914243
Drug: Low-dose dexmedetomidine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexmedetomidine + Hydromorphone (DM + HM)
Study: 33769656
Drug: Henagliflozin 5
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Henagliflozin 5 mg
Study: 34489928
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC-AC) without DCs (control group)
Study: 37477771
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg
Study: 34275122
Drug: Baricitinib 1
Normalized name: baricitinib 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 1 mg
Study: 33058553
Drug: Miglitol reference
Normalized name: Miglitol
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miglitol reference formulation/sucrose coadministration
Study: 33058553
Drug: Sucrose administration
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose administration alone
Study: 33837482
Drug: Cyclosporine 5
Normalized name: cyclosporine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 5 mg/(kg·d) plus andriol 160 mg/d
Study: 36152639
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (100 U/mL)
Study: 38745322
Drug: Mirror Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror Therapy (MT)
Study: 33768368
Drug: Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone Propionate Dry Powder Inhaler A-4.5 (500 μg)
Study: 33768368
Drug: Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone Propionate Dry Powder Inhaler C-3.7 (500 μg)
Study: 34293528
Drug: Subcutaneous immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunoglobulin (IgPro20) at 0.2 g/kg
Study: 32780166
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C (50 mg/kg, maximum single dose 3 g) and thiamine (200 mg) every 12 h for 48 h
Study: 39707407
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (placebo)
Study: 38195586
Drug: Intravenous aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous aspirin
Study: 38884900
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of physician's choice (TPC)
Study: 36164012
Drug: Danazol (DAN)
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol (DAN) 600 mg QD
Study: 36164012
Drug: Momelotinib (MMB)
Normalized name: momelotinib
DrugBank: Momelotinib (DB11763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Momelotinib (MMB) 200 mg QD
Study: 34473249
Drug: Early rhythm
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early rhythm control therapy (antiarrhythmic drugs and AF ablation)
Study: 34473249
Drug: Early rhythm
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early rhythm control therapy
Study: 34469706
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days of intravenous antimicrobials
Study: 34404592
Drug: Maintaining serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintaining serum potassium at ≥4.5 mEq/L
Study: 32048274
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of iv dexamethasone 24 mg
Study: 39147988
Drug: Allopurinol administration
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol administration
Study: 38584159
Drug: Candesartan 8
Normalized name: candesartan 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8 mg
Study: 35405955
Drug: Isotretinoin combined
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin combined with evening primrose oil (4 × 510 mg/day)
Study: 35361328
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (FKB238, EU-bevacizumab, US-bevacizumab)
Study: 37449048
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg/day
Study: 35101364
Drug: Pertuzumab plus
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab plus trastuzumab plus metronomic chemotherapy (TPM)
Study: 36026559
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine - two injections once every two weeks
Study: 35172876
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride 0.9% solution (placebo, 0.1-0.3 ml per injection)
Study: 35468803
Drug: ANI group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANI group (goal-directed analgesia targeting 50-80 ANI range with prophylactic morphine if ANI < 50)
Study: 35341360
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy (MT)
Study: 32664057
Drug: High-dissolution turmeric-sesame
Normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dissolution turmeric-sesame formulation (Rhuleave-K; 1,000 mg/d)
Study: 37339352
Drug: Low Level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Level Laser Therapy (LLLT)
Study: 33384385
Drug: SAFE intervention
Normalized name: Safe-Guard
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAFE intervention (five-session family therapy-based intervention delivered over 16 weeks)
Study: 37025023
Drug: Aspirin 81
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81 mg
Study: 32468508
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of hyperimmune plasma from convalescent donors of COVID-19
Study: 35252940
Drug: Any hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Any hormone or SHBG
Study: 34716885
Drug: Reminiscence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscence therapy involved care (RTIC)
Study: 34264305
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg once daily for 2 years
Study: 35172056
Drug: EDP-938 300
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP-938 300 mg once daily after a 600 mg loading dose
Study: 33044356
Drug: Trazodone 50
Normalized name: traZODone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone 50 mg daily for 5 days
Study: 35300246
Drug: Trimodal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimodal therapy consisting of IMRT, gemcitabine and cetuximab
Study: 32616489
Drug: Placebo, one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, one tablet each day for a total duration of 6 months
Study: 36155150
Drug: l-carnitine
Normalized name: L-Carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: l-carnitine
Study: 39151647
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy
Study: 34756178
Drug: IL-1 blockade
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-1 blockade (anakinra 100 mg subcutaneously once daily for 28 days)
Study: 37579130
Drug: Selective Serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective Serotonin Reuptake Inhibitors (SSRIs)
Study: 37028515
Drug: Best available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Best available therapy (BAT)
Study: 34133205
Drug: Standard-dose gadoterate
Normalized name: GADOTERATE
DrugBank: Gadoteric acid (DB09132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose gadoterate
Study: 34101892
Drug: Rivoceranib 201
Normalized name: Rivoceranib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivoceranib 201 mg without food
Study: 34101892
Drug: Rivoceranib 81
Normalized name: Rivoceranib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivoceranib 81 mg with food
Study: 34101892
Drug: Rivoceranib 81
Normalized name: Rivoceranib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivoceranib 81 mg without food
Study: 37951571
Drug: Omalizumab treatment
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab treatment
Study: 36174602
Drug: Higher enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher enoxaparin doses
Study: 34400254
Drug: N-of-1 trial
Normalized name: (Alginate)n+1
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-of-1 trial treatment regimen
Study: 38057919
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine
Study: 36214032
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (120 kVp, 370 mgI/ml CM)
Study: 34674645
Drug: Weekly multidisciplinary
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly multidisciplinary team‐led deprescribing rounds (using five steps of deprescribing)
Study: 34582035
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA)
Study: 32505790
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of OES and HYbiopsy
Study: 35836116
Drug: ESP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESP block with 0.375% ropivacaine (0.4 mL/kg)
Study: 35287254
Drug: Thoracic radiotherapy
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic radiotherapy dose >54 Gy
Study: 37304043
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg
Study: 34416778
Drug: Ibuprofen suppository
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen suppository
Study: 34022840
Drug: Digital alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digital alcohol moderation intervention + Treatment as Usual (TAU)
Study: 35022886
Drug: Life-sustaining treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life-sustaining treatment (LST)
Study: 35747181
Drug: 2-dose measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose measles vaccination (MV) at 4 and 9 months
Study: 34453262
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.025% formulation 13
Study: 33319949
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous morphine analgesia
Study: 39516087
Drug: Best Available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Best Available Therapy (BAT)
Study: 38832995
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of adenosine
Study: 32128615
Drug: Aprepitant (APR)
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant (APR) 125 mg on day 1 and 80 mg on days 2-3
Study: 33181328
Drug: Favipiravir combined
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Favipiravir combined with inhaled interferon beta-1b
Study: 39641404
Drug: Daridorexant 50
Normalized name: daridorexant 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daridorexant 50 mg
Study: 32341187
Drug: Daridorexant 10
Normalized name: Daridorexant
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daridorexant 10 mg
Study: 35357079
Drug: Low-dose Lomecel-B
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Lomecel-B
Study: 32815805
Drug: Locked plating
Normalized name: platinic chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locked plating followed by intraoperatively performed glenohumeral joint lavage (group L)
Study: 32815805
Drug: Avascular necrosis
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avascular necrosis in group L
Study: 32293522
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root-planing treatment
Study: 32035551
Drug: Biological mesh
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological mesh reinforcement
Study: 35233908
Drug: ertugliflozin 5
Normalized name: ertugliflozin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ertugliflozin 5 mg
Study: 32493494
Drug: Hydroxychloroquine 200mg
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine 200mg once daily for two months (HC group)
Study: 33899214
Drug: Dexamethasone 20
Normalized name: dexamethasone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 20 mg pre-operatively
Study: 32268344
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of levodopa
Study: 34060339
Drug: Penile traction
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penile traction therapy
Study: 35650437
Drug: Combination broadly
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination broadly neutralizing monoclonal antibodies (3BNC117 and 10-1074), administered up to 8 infusions over 24 weeks.
Study: 32212275
Drug: TransCon PTH
Normalized name: TransCon PTH
DrugBank: Palopegteriparatide (DB18676)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TransCon PTH (administered daily for 10 days)
Study: 34449946
Drug: Vitrification treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitrification treatment
Study: 35349757
Drug: Ganciclovir treatment
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir treatment
Study: 39715755
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (chemotherapy alone)
Study: 34403326
Drug: Isoniazid 5
Normalized name: isoniazid 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid 5 mg/kg (normal dose)